Organogenesis Hldgs Inc Stock Price, News & Analysis

Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

Management will conduct a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update, followed by a Q&A session. The event will be accessible via webcast through the company's investor relations website, where it will remain archived for approximately one year.

Organogenesis Holdings (NASDAQ: ORGO) reported strong Q4 2024 financial results with net revenue of $126.7 million, up 27% from Q4 2023. The company achieved Q4 net income of $7.7 million compared to a net loss of $0.6 million in Q4 2023.

For full-year 2024, revenue reached $482.0 million, an 11% increase from 2023, driven by Advanced Wound Care products (+12% to $453.6M) and Surgical & Sports Medicine products (+3% to $28.4M). The company ended 2024 with $136.2 million in cash and no outstanding debt.

For 2025 guidance, Organogenesis expects:

• Net revenue between $480.0-$535.0 million
• Net income between $9.5-$38.8 million
• Adjusted EBITDA between $43.6-$83.2 million

Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on February 27th, 2025.

Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly and annual results, provide a corporate update, and conduct a Q&A session. The event will be accessible via live webcast through the company's investor relations website, where it will remain archived for approximately one year.

Organogenesis Holdings (Nasdaq: ORGO) announced plans to expand its manufacturing capacity through a long-term lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. The regenerative medicine company, which focuses on Advanced Wound Care and Surgical and Sports Medicine markets, will maintain its existing operations across multiple locations including Massachusetts, Alabama, California, Florida, and Switzerland. The Rhode Island expansion is subject to state and local tax incentives.

Organogenesis Holdings (Nasdaq: ORGO) welcomes the U.S. Centers for Medicare & Medicaid Services' decision on local coverage determination (LCD) for skin substitute grafts and cellular tissue-based products treating diabetic foot ulcers and venous leg ulcers. The LCD, effective February 12, 2025, is based on peer-reviewed clinical efficacy data. Organogenesis offers 4 products for diabetic foot ulcers, including NuShield, and 2 for venous leg ulcers. The company's NuShield product has been added to the list of covered products, marking a positive development for both the company and industry.

Organogenesis Holdings (NASDAQ: ORGO) reported Q3 2024 financial results with net revenue of $115.2 million, up 6% from Q3 2023. Advanced Wound Care revenue increased 7% to $108.0 million, while Surgical & Sports Medicine revenue grew 1% to $7.2 million. Net income reached $12.3 million ($0.09 per share), up from $3.2 million in Q3 2023. Adjusted EBITDA was $13.4 million, down from $16.0 million year-over-year. The company updated its FY2024 guidance, expecting net revenue between $455-480 million, representing 5-11% growth, with projected net loss between $12.3-0.6 million.

Organogenesis Holdings (Nasdaq: ORGO) has secured a $130 million private placement through the sale of Series A Convertible Preferred Stock to Avista Healthcare Partners. The net proceeds will fund strategic growth initiatives, including operating activities, clinical development, working capital, and debt repayment. $23.5 million will be used to repurchase 7.4 million shares of common stock from certain directors. The Preferred Stock is convertible into common stock at $3.79 per share, a 20% premium to recent trading. Investors will receive an 8% annual dividend, and Garrett Lustig from Avista joins the Board of Directors.

Organogenesis Holdings (ORGO) announced positive interim analysis results from its second Phase 3 clinical trial of ReNu for knee osteoarthritis treatment. The analysis, covering 50% of 474 planned patients with moderate to severe knee OA, focused on the 6-month primary endpoint. The independent Data Monitoring Committee recommended proceeding without modifications or sample size increases, confirming favorable results and consistent safety profile. The fully enrolled 594-patient trial is evaluating ReNu versus saline control through intra-articular injection, with the primary endpoint measuring knee pain reduction using the WOMAC pain scale. Knee OA affects nearly 31.1 million Americans, projected to reach 34.4 million by 2027.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company, has announced that it will report its third quarter fiscal year 2024 financial results after the market closes on Tuesday, November 12th, 2024. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the quarterly results and provide a corporate update, followed by a question and answer session.

Interested parties can access the live webcast through the company's website at investors.organogenesis.com or via a provided link. A teleconference option is also available. The webcast will be archived on the company's website for approximately one year after the event.